Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer — Stella

Recruiting

Back to Gastric Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality

Key details

Phase

Safety & dosing

Sponsor

Fudan University

Enrollment target

~114 participants

Started

January 2023

Primary completion

January 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

20 Years – 80 Years

Last updated March 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov